The World Health Organisation (WHO) has approved the use of dexamethasone to treat critically ill Covid-19 patients. WHO made the announcement through its director-general, Tedros Ghebreyesus, on Monday, June 22, during a virtual briefing.
According to the global health agency, recent findings have shown that the “steroid dexamethasone has life-saving potential for critically ill COVID-19 patients.” WHO DG, however, stated that the use is in its preliminary stage, adding that dexamethasone has shown huge benefit in the United Kingdom in what gives the world the reason to celebrate.
“There is no evidence this drug works for patients with mild disease or as a preventative measure, and it could cause harm. The global agency announced that dexamethasone can now be used to treat critically ill Covid-19 patients. Source: UGC “Fortunately, this is an inexpensive medicine and there are many dexamethasone manufacturers worldwide, who we are confident can accelerate production,” the WHo DG said.
Meanwhile, there are 9,218,565 cases of Covid-19 in the world with the United States standing tall on the log with 2,388,225 cases. 474,966 deaths have been recorded globally, while 4,961,952 people have recovered from the virus.
WHO said it has finally halted hydroxychloroquine trial for Covid-19 treatment. The global health agency made the declaration on Wednesday, June 17, in a tweet, saying the drug is not effective in treating the highly-ravaging infection.